CPG on ADHD

More documents

Recommendations

Info

Clinical Practice Guidelineon Attention DeficitHyperactivity Disorder(ADHD) in Children andAdolescentsCLINICAL PRACTICE GUIDELINES IN THE SPANISH NHSMINISTRY OF HEALTH AND SOCIAL POLICIESMINISTERIODE SANIDAD, POLÍTICA SOCIALE IGUALDAD
Page 4 and 5: This CPG is a heal
Page 7 and 8: Table of contentsPresentation 7Auth
Page 9 and 10: PresentationHealthcare practice is
Page 11 and 12: Authorship and CollaboratorsDevelop
Page 13: Declaration of interest: All the me
Page 16 and 17: TREATMENTPsychological treatment19.
Page 18 and 19: 58. What precautions must be taken,
Page 20 and 21: 5.3. Which evaluation areas must be
Page 22 and 23: Cognitive behavioural therapy is re
Page 24 and 25: 7.3.3. In ADHD: How effective are p
Page 26 and 27: 7.3.10. In which ADHD subtypes is p
Page 28 and 29: 7.3.18. What clinical variables and
Page 30 and 31: 8. PreventionRecommendationsIt is a
Page 32 and 33: Applicablelegislativeframework9.5.4
Page 34 and 35: ADHD represents a public health pro
Page 36 and 37: 12.5% of the children diagnosed wit
Page 39 and 40: 2. Scope and objectivesTarget popul
Page 41 and 42: 3. MethodologyThe methodology used
Page 43 and 44: Exclusion criteria:• Studies on d
Page 45 and 46: 4. ADHDQuestions to be answered:4.1
Page 47 and 48: • ADHD-I: The inattentive subtype
Page 49 and 50: Dietetic factors such as the type o
Page 51 and 52: hyperactive children had significan
Page 53:
4.6. In ADHD: What are the most fre
Page 56 and 57:
Both classification systems coincid
Page 58 and 59:
RecommendationsD 5.2.1.D 5.2.2.The
Page 60 and 61:
Psychopathological examinationSumma
Page 62 and 63:
5.5. In the diagnosis of ADHD in ch
Page 65 and 66:
6. Assessment instrumentsQuestions
Page 67 and 68:
Table 4. Specific scales, general p
Page 69 and 70:
Title Authors Year Description Age
Page 71 and 72:
Title Authors Year Description Age
Page 73 and 74:
Table 5. Intelligence and neuropsyc
Page 75:
NameAuthor / publishinghouse / year
Page 78 and 79:
Cognitive therapy with childrenThe
Page 80 and 81:
Variable: Behavioural symptoms (ODD
Page 82 and 83:
In 2006, NICE 168 published an asse
Page 84 and 85:
7.1.3. Psychological treatment of c
Page 86 and 87:
Summary of scientific evidenceThere
Page 88 and 89:
7.1.5. In ADHD in children and adol
Page 90 and 91:
More specific interventions have al
Page 92 and 93:
Page 94 and 95:
2002 184 ; Tymms, 2006) 185 . This
Page 96 and 97:
Page 98 and 99:
7.3.1. What drugs for ADHD are avai
Page 100 and 101:
This does not modify the bioavailab
Page 102 and 103:
of 0.44% in patients treated with a
Page 104 and 105:
Variable: Behavioural problemsScien
Page 106 and 107:
Atomoxetine:The NICE CPG</s
Page 108 and 109:
There is limited scientific evidenc
Page 110 and 111:
Variable: Behavioural problemsScien
Page 112 and 113:
Modafi nilThe NICE CPG</str
Page 114 and 115:
Cost-effectiveness studiestScientif
Page 116 and 117:
7.3.3. In ADHD: How effective are p
Page 118 and 119:
7.3.5. In ADHD: What criteria are u
Page 120 and 121:
7.3.6. What are the most frequent (
Page 122 and 123:
One accepted practice is to leave s
Page 124 and 125:
There is no scientific evidence to
Page 126 and 127:
7.3.12. Which physical parameters (
Page 128 and 129:
7.3.14. Pharmacological treatment o
Page 130 and 131:
7.3.16. Do the effects remain after
Page 132 and 133:
7.4. Combined treatmentQuestions to
Page 134 and 135:
Variable: Clinical improvement at t
Page 136 and 137:
Variable: Clinical improvement 13 t
Page 138 and 139:
Clinical evidence of intensive comb
Page 140 and 141:
There is not sufficient scientific
Page 142 and 143:
Clinical evidence of intensive comb
Page 144 and 145:
There is not sufficient scientific
Page 146 and 147:
measurements of social skills, whic
Page 148 and 149:
7.5. Comorbidity treatmentQuestions
Page 150 and 151:
7.5.3. In children and adolescents
Page 152 and 153:
7.5.5. In children and adolescents
Page 154 and 155:
7.6. Complementary and alternative
Page 156 and 157:
Summary of the scientific evidenceT
Page 158 and 159:
RecommendationsD 7.6.2.1.D 7.6.2.2.
Page 161 and 162:
9. Ethical and legal aspectsQuestio
Page 163 and 164:
In the extreme case of needing to a
Page 165 and 166:
ApplicablelegalframeworkApplicablel
Page 167 and 168:
Algorithm 2. Treatment of ADHD in c
Page 169:
List of abbreviations of the algori
Page 172 and 173:
Table 12. Indicators proposedProces
Page 174 and 175:
• Development of standardised neu
Page 177 and 178:
AppendicesCLINICAL PRACTICE GUIDELI
Page 179 and 180:
Appendix 2. Diagnostic criteria for
Page 181 and 182:
Impulsivity1. Often blurts out answ
Page 183 and 184:
• ADHD, combined type:The three m
Page 185 and 186:
sity, which are usually administere
Page 187 and 188:
• Working on habits that foster a
Page 189 and 190:
Although the treatment is personali
Page 191 and 192:
The early detection of the disorder
Page 193 and 194:
• Bauermeister JJ. Hiperactivo, i
Page 195 and 196:
In case and control studies, a cont
Page 197 and 198:
Observational study (synonym: non-e
Page 199 and 200:
obtain and analyse the data of the
Page 201 and 202:
CNSCPGCPRSCPT IICr
Page 203 and 204:
SRSSSSRISTROOPSUDTADTALETALECTPTRFU
Page 205 and 206:
Marta Garcia Giral has received aid
Page 207 and 208:
Appendix 7. Description of the <str
Page 209 and 210:
Canadian ADHD Practice Guidelines 3
Page 211 and 212:
Bibliography1. Scottish Intercolleg
Page 213 and 214:
35. Mannuzza S, Klein RG, Bessler A
Page 215 and 216:
67. Millichap JG. Etiologic classif
Page 217 and 218:
101. Biederman J, Mick E, Faraone S
Page 219 and 220:
2000;2: 95-100.135. Herjanic B, Rei
Page 221 and 222:
163. Horn WF, Ialongo N, Greenberg
Page 223 and 224:
197. Connor DF, Glatt SJ, Lopez ID,
Page 225 and 226:
228. Kolko DJ, Bukstein OG, Barron
Page 227 and 228:
256. Michelson D, Buitelaar JK, Dan
Page 229 and 230:
J Child Psychol Psychiatry. 1980 Ja
Page 231 and 232:
moxetine on growth after 2-year tre
Page 233 and 234:
Deficit/Hyperactivity Disorder in C
show all

CPG on ADHD

Create successful ePaper yourself

Delete template?

Save as template?